XmAb 2513 Completed Phase 1 Trials for Lymphoma, Hodgkins / Large Cell Anaplastic Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00606645Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma